MedlinePlus gives the same general site-quality warning for subcutaneous injections: the site should be healthy and free of visible damage
Adding cagrilintide to tirzepatide Theoretical protocol (not clinically studied): If on tirzepatide 10-15mg: Stable on tirzepatide for 4+ weeks Continue tirzepatide at current dose Add cagrilintide 0.6mg weekly Standard cagrilintide titration to 2.4mg Rationale: Tirzepatide is dual GIP/GLP-1 (very powerful alone) Adding amylin pathway could theoretically enhance No clinical data on this combination Uncertain if additional benefit over tirzepatide alone Concerns: GI side effects may be severe (both slow gastric emptying) Tirzepatide already produces 15-22% weight loss alone Unclear if cagrilintide adds meaningful benefit Expensive combination Verdict: Wait for clinical data
Also avoid injecting directly into stretch marks, moles, tattoos, open wounds, surgical scars, or any area with unusual pain or texture
The 5mg lyophilised presentation is the standard format used in the published reference literature for BPC-157, making it the most straightforward option for researchers reproducing or extending existing study designs
DSIP has not provided one
Normally, GHK-Cu's collagen-stimulating effects outweigh this degradation
